$HRMY
Harmony Biosciences Holdings Inc

2023 Q4 Form 10-Q Financial Statement

#000155837023017060 Filed on October 31, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $168.4M $160.3M
YoY Change 31.26% 36.74%
Cost Of Revenue $43.15M $32.30M
YoY Change 60.51% 40.67%
Gross Profit $125.3M $128.0M
YoY Change 23.5% 35.78%
Gross Profit Margin 74.38% 79.85%
Selling, General & Admin $54.76M $45.96M
YoY Change 45.03% 9.97%
% of Gross Profit 43.72% 35.92%
Research & Development $30.31M $17.50M
YoY Change 200.3% -56.84%
% of Gross Profit 24.19% 13.67%
Depreciation & Amortization $6.059M $6.200M
YoY Change -0.15% 2.26%
% of Gross Profit 4.84% 4.84%
Operating Expenses $85.06M $63.46M
YoY Change 58.08% -22.93%
Operating Profit $40.20M $64.51M
YoY Change -15.58% 442.05%
Interest Expense -$700.0K -$2.906M
YoY Change -80.46% -27.17%
% of Operating Profit -1.74% -4.5%
Other Income/Expense, Net $193.0K -$5.000K
YoY Change 164.38% -108.93%
Pretax Income $39.69M $51.83M
YoY Change -10.01% 550.58%
Income Tax $13.08M $13.37M
% Of Pretax Income 32.96% 25.8%
Net Earnings $26.61M $38.46M
YoY Change -45.15% -56.27%
Net Earnings / Revenue 15.8% 24.0%
Basic Earnings Per Share $0.64
Diluted Earnings Per Share $0.45 $0.63
COMMON SHARES
Basic Shares Outstanding 58.57M 60.00M
Diluted Shares Outstanding 60.68M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $353.5M $370.7M
YoY Change 9.39% 20.45%
Cash & Equivalents $311.7M $324.6M
Short-Term Investments $41.80M $46.10M
Other Short-Term Assets $5.537M $5.704M
YoY Change -36.98% 38.85%
Inventory $5.363M $5.087M
Prepaid Expenses $12.57M $14.27M
Receivables $74.14M $67.26M
Other Receivables $0.00 $0.00
Total Short-Term Assets $451.1M $463.0M
YoY Change 12.69% 21.18%
LONG-TERM ASSETS
Property, Plant & Equipment $371.0K $428.0K
YoY Change -35.25% -37.06%
Goodwill
YoY Change
Intangibles $137.1M $143.1M
YoY Change -14.81% -14.29%
Long-Term Investments $72.17M $67.70M
YoY Change 219.78% 717.63%
Other Assets $6.298M $2.836M
YoY Change 125.09% -7.89%
Total Long-Term Assets $360.4M $314.8M
YoY Change 31.72% 20.42%
TOTAL ASSETS
Total Short-Term Assets $451.1M $463.0M
Total Long-Term Assets $360.4M $314.8M
Total Assets $811.4M $777.8M
YoY Change 20.42% 20.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.73M $6.539M
YoY Change 368.3% -34.93%
Accrued Expenses $124.7M $72.76M
YoY Change 108.0% -15.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $15.00M $15.00M
YoY Change 650.0% 650.0%
Total Short-Term Liabilities $163.8M $112.4M
YoY Change 107.62% 4.7%
LONG-TERM LIABILITIES
Long-Term Debt $178.6M $182.1M
YoY Change -5.84% -4.0%
Other Long-Term Liabilities $2.109M $1.895M
YoY Change -15.67% -24.14%
Total Long-Term Liabilities $180.7M $184.0M
YoY Change -5.97% -4.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $163.8M $112.4M
Total Long-Term Liabilities $180.7M $184.0M
Total Liabilities $344.5M $296.4M
YoY Change 27.09% -1.05%
SHAREHOLDERS EQUITY
Retained Earnings -$143.3M -$169.9M
YoY Change -47.35% -47.02%
Common Stock $610.3M $651.7M
YoY Change -9.61% -1.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $467.0M $481.3M
YoY Change
Total Liabilities & Shareholders Equity $811.4M $777.8M
YoY Change 20.42% 20.87%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income $26.61M $38.46M
YoY Change -45.15% -56.27%
Depreciation, Depletion And Amortization $6.059M $6.200M
YoY Change -0.15% 2.26%
Cash From Operating Activities $76.69M $63.10M
YoY Change 187.45% 14.3%
INVESTING ACTIVITIES
Capital Expenditures $112.0K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$35.93M -$800.0K
YoY Change -23.39% -97.53%
Cash From Investing Activities -$36.04M -$800.0K
YoY Change -23.15% -97.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -53.55M -55.10M
YoY Change -2114.75% -2787.8%
NET CHANGE
Cash From Operating Activities 76.69M 63.10M
Cash From Investing Activities -36.04M -800.0K
Cash From Financing Activities -53.55M -55.10M
Net Change In Cash -12.90M 7.200M
YoY Change -26.51% -70.98%
FREE CASH FLOW
Cash From Operating Activities $76.69M $63.10M
Capital Expenditures $112.0K $0.00
Free Cash Flow $76.58M $63.10M
YoY Change 187.03% 14.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2022Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
dei Entity Central Index Key
EntityCentralIndexKey
0001802665
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q3 us-gaap Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration
OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Other Receivable After Allowance For Credit Loss Related Party Type Extensible Enumeration
OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q3 us-gaap Other Liability Related Party Type Extensible Enumeration
OtherLiabilityRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4 us-gaap Other Liability Related Party Type Extensible Enumeration
OtherLiabilityRelatedPartyTypeExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39450
dei Entity Registrant Name
EntityRegistrantName
HARMONY BIOSCIENCES HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2279923
dei Entity Address Address Line1
EntityAddressAddressLine1
630 W.
dei Entity Address Address Line2
EntityAddressAddressLine2
Germantown Pike
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 215
dei Entity Address City Or Town
EntityAddressCityOrTown
Plymouth Meeting
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19462
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
539-9800
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 value per share
dei Trading Symbol
TradingSymbol
HRMY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58571944
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
324603000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
243784000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
46071000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
79331000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
67264000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
54740000
CY2023Q3 us-gaap Inventory Net
InventoryNet
5087000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4297000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
14269000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9347000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
5704000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8786000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
462998000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
400285000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
428000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
573000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
250000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q3 us-gaap Long Term Investments
LongTermInvestments
67700000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
22568000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
143069000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
160953000
CY2023Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
100485000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
85943000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2836000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2798000
CY2023Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
314768000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
273585000
CY2023Q3 us-gaap Assets
Assets
777766000
CY2022Q4 us-gaap Assets
Assets
673870000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6539000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3786000
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
10322000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
11532000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
72761000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
59942000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
15000000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7786000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1624000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
112408000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78884000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
182131000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189647000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1895000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2501000
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
184026000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
192148000
CY2023Q3 us-gaap Liabilities
Liabilities
296434000
CY2022Q4 us-gaap Liabilities
Liabilities
271032000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58571944
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58571944
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59615731
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59615731
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
651731000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
675118000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-516000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-151000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169884000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-272130000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
481332000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
402838000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
777766000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
673870000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
160268000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
117206000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
413610000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
309547000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32296000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
22959000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
78084000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
56596000
CY2023Q3 us-gaap Gross Profit
GrossProfit
127972000
CY2022Q3 us-gaap Gross Profit
GrossProfit
94247000
us-gaap Gross Profit
GrossProfit
335526000
us-gaap Gross Profit
GrossProfit
252951000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17499000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40548000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45757000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60794000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
23418000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20467000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
70518000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
58210000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22546000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21331000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
67417000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
61374000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
63463000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
82346000
us-gaap Operating Expenses
OperatingExpenses
183692000
us-gaap Operating Expenses
OperatingExpenses
180378000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
64509000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
11901000
us-gaap Operating Income Loss
OperatingIncomeLoss
151834000
us-gaap Operating Income Loss
OperatingIncomeLoss
72573000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9766000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9766000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
56000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-34000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
96000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2906000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-3990000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8327000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-12086000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
51832000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7967000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
133707000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
60583000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13371000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-79976000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31461000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-72376000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
38461000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
87943000
us-gaap Net Income Loss
NetIncomeLoss
102246000
us-gaap Net Income Loss
NetIncomeLoss
132959000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-149000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-365000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-178000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
38467000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
87794000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
101881000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
132781000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.64
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.25
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.63
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.18
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59863102
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59234720
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59856941
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59070063
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60681676
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61207625
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60892992
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60921482
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
402838000
us-gaap Net Income Loss
NetIncomeLoss
102246000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-365000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
50543000
hrmy Stock Issued During Period Value Stock Options And Restricted Stock Units Exercised
StockIssuedDuringPeriodValueStockOptionsAndRestrictedStockUnitsExercised
4314000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22842000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
481332000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
485172000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
38461000
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6000
CY2023Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
50543000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
245000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7991000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
481332000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186507000
us-gaap Net Income Loss
NetIncomeLoss
132959000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-178000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
408000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5275000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18913000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
343884000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
246533000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
87943000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-149000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
408000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2143000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7006000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
343884000
us-gaap Profit Loss
ProfitLoss
102246000
us-gaap Profit Loss
ProfitLoss
132959000
us-gaap Depreciation
Depreciation
350000
us-gaap Depreciation
Depreciation
312000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17884000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17005000
us-gaap Share Based Compensation
ShareBasedCompensation
22842000
us-gaap Share Based Compensation
ShareBasedCompensation
18913000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
-531000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
321000
hrmy Adjustment For Amortization Of Debt Issuance Costs
AdjustmentForAmortizationOfDebtIssuanceCosts
2089000
hrmy Adjustment For Amortization Of Debt Issuance Costs
AdjustmentForAmortizationOfDebtIssuanceCosts
1241000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-14542000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-81679000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2031000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9766000
us-gaap Other Noncash Expense
OtherNoncashExpense
1258000
us-gaap Other Noncash Expense
OtherNoncashExpense
1042000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12524000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
20222000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
790000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-532000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1759000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4704000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2753000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
9048000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
15714000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
43171000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-3000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-151000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
142722000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
117788000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
105856000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
55637000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
95687000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
872000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
205000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
172000
hrmy Cash Paid For Milestones
CashPaidForMilestones
40000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10374000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-94937000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
408000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
200000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2997000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
196500000
hrmy Payments Of Extinguishment Of Debt Exit Fees
PaymentsOfExtinguishmentOfDebtExitFees
5846000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1500000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
50000000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
514000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4828000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5275000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-52029000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4183000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
80319000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27034000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
244534000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235059000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
324853000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
262093000
us-gaap Interest Paid Net
InterestPaidNet
15653000
us-gaap Interest Paid Net
InterestPaidNet
11334000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
36543000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
9702000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169884000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-272130000
CY2023Q3 us-gaap Investments And Cash
InvestmentsAndCash
438374000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes. </p>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
324603000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
243784000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
250000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
324853000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
244534000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3384000
us-gaap Investment Income Interest
InvestmentIncomeInterest
8537000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
828000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1145000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Substantially all of the Company’s cash and money market funds are held in four financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company believes that it is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored, and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary. As of September 30, 2023, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 37% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 37% of gross accounts receivable; and PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 26% of gross accounts receivable. As of December 31, 2022, three customers accounted for 100% of gross accounts receivable; CVS Caremark, which accounted for 41% of gross accounts receivable, Accredo, which accounted for 35% of gross accounts receivable; and Pantherx, which accounted for 24% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2023, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 37% of gross product revenues; Accredo accounted for 32% of gross product revenues; and Pantherx accounted for 31% of gross product revenues. For the nine months ended September 30, 2022, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 40% of gross product revenues; Pantherx accounted for 30% of gross product revenues; and Accredo accounted for 30% of gross product revenues.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single source supplier for each of its product and active pharmaceutical ingredient.</p>
hrmy Concentrations Of Risk Number Of Financial Institutions
ConcentrationsOfRiskNumberOfFinancialInstitutions
4
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
311906000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
286876000
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
932000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
838000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1833000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1513000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2611000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2565000
CY2023Q3 us-gaap Inventory Gross
InventoryGross
5376000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
4916000
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
289000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
619000
CY2023Q3 us-gaap Inventory Net
InventoryNet
5087000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4297000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5962000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5961000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17884000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17884000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17005000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
5961000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
23845000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
23845000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
23845000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
23845000
CY2023Q3 hrmy Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
41728000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
143069000
CY2023Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
71931000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
54047000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
143069000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
160953000
CY2023Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
29665000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
25367000
CY2023Q3 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
31853000
CY2022Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
27860000
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
3140000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
3286000
CY2023Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2253000
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1135000
CY2023Q3 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2190000
CY2022Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
358000
CY2023Q3 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1841000
CY2022Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1163000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1819000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
773000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
72761000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
59942000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
200000000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
197500000
CY2023Q3 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
2869000
CY2022Q4 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
5853000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
197131000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
191647000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
15000000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
182131000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189647000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
3750000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
15000000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
16250000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
20000000
CY2023Q3 hrmy Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
125000000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
200000000
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4791000
CY2022Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4513000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
15900000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
12110000
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2221000
CY2022Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
418000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3061000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1241000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
7012000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4931000
us-gaap Interest Expense Debt
InterestExpenseDebt
18961000
us-gaap Interest Expense Debt
InterestExpenseDebt
13351000
CY2018Q2 hrmy Operating Lease Office Space
OperatingLeaseOfficeSpace
15000
CY2018Q2 hrmy Operating Lease Additional Office Space Leased One
OperatingLeaseAdditionalOfficeSpaceLeasedOne
13000
CY2018Q2 hrmy Operating Lease Additional Office Space Leased Two
OperatingLeaseAdditionalOfficeSpaceLeasedTwo
7000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
473000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
378000
us-gaap Operating Lease Cost
OperatingLeaseCost
1295000
us-gaap Operating Lease Cost
OperatingLeaseCost
1155000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2456000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2312000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1683000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1614000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
901000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
975000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2584000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2589000
us-gaap Operating Lease Payments
OperatingLeasePayments
1448000
us-gaap Operating Lease Payments
OperatingLeasePayments
1297000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1592000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
485000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
558000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1407000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
532000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
252000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2749000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
165000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2584000
CY2023Q3 hrmy Common Stock Number Of Votes Per Share
CommonStockNumberOfVotesPerShare
1
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6460947
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.90
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M9D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
376422
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
36.71
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
367376
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
12.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
206318
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
24.84
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6263675
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.55
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M20D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7632
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8021
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7257
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7708
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0342
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0461
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0199
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0405
hrmy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount
0.0000
CY2022 hrmy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Lack Of Marketability Discount
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsLackOfMarketabilityDiscount
0.0000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59070063
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7957000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6967000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22311000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19234000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
67842000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
14043
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
14889
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
38461000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
87943000
us-gaap Net Income Loss
NetIncomeLoss
102246000
us-gaap Net Income Loss
NetIncomeLoss
132959000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.64
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.25
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.63
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.18
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59863102
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59234720
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59856941
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60681676
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61207625
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60892992
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60921482
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
818574
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1972905
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1036051
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1851419
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.170
us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.009
us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.044
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.221
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.005
CY2023Q3 hrmy Effective Income Tax Rate Reconciliation Credits
EffectiveIncomeTaxRateReconciliationCredits
0.002
hrmy Effective Income Tax Rate Reconciliation Credits
EffectiveIncomeTaxRateReconciliationCredits
-0.016
hrmy Effective Income Tax Rate Reconciliation Credits
EffectiveIncomeTaxRateReconciliationCredits
-0.002
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.006
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.003
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.007
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-9.857
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1.449
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.258
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-10.038
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.235
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-1.195
CY2023Q3 us-gaap Other Liabilities
OtherLiabilities
0
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
0
CY2023Q3 us-gaap Other Receivables
OtherReceivables
0
CY2022Q4 us-gaap Other Receivables
OtherReceivables
0
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-23-017060-index-headers.html Edgar Link pending
0001558370-23-017060-index.html Edgar Link pending
0001558370-23-017060.txt Edgar Link pending
0001558370-23-017060-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hrmy-20230930.xsd Edgar Link pending
hrmy-20230930x10q.htm Edgar Link pending
hrmy-20230930xex31d1.htm Edgar Link pending
hrmy-20230930xex31d2.htm Edgar Link pending
hrmy-20230930xex32d1.htm Edgar Link pending
hrmy-20230930xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
hrmy-20230930_cal.xml Edgar Link unprocessable
hrmy-20230930_def.xml Edgar Link unprocessable
hrmy-20230930_pre.xml Edgar Link unprocessable
hrmy-20230930x10q_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hrmy-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable